Two Biosimilars to Denosumab Win FDA Approval as Amgen and Sandoz Go to Court
Biosimilars Wyost and Jubobonti were approved as interchangeable for Xgeva and Prolia but launch will depend on the outcome of litigation between reference product manufacturers.
Alzheimer Drug Lecanemab Granted Full FDA Approval
FDA's action, based on confirmatory evidence showing slowed disease progression, follows a January 2023 accelerated approval.
LAMA-LABA Treatment for COPD More Effective than ICS-LBA: New Findings
Results of a new study offer additional support for clinical guidelines to favor one therapy over another, authors suggest.
